Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Treasury Shares (2017 - 2025)

Historic Treasury Shares for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $1.4 million.

  • Puma Biotechnology's Treasury Shares fell 47.39% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 47.39%. This contributed to the annual value of $1.3 million for FY2024, which is 2064.79% down from last year.
  • Latest data reveals that Puma Biotechnology reported Treasury Shares of $1.4 million as of Q3 2025, which was down 47.39% from $1.8 million recorded in Q2 2025.
  • Puma Biotechnology's Treasury Shares' 5-year high stood at $2.5 million during Q1 2021, with a 5-year trough of $1.3 million in Q4 2024.
  • For the 5-year period, Puma Biotechnology's Treasury Shares averaged around $1.8 million, with its median value being $1.9 million (2025).
  • Per our database at Business Quant, Puma Biotechnology's Treasury Shares tumbled by 2453.28% in 2021 and then soared by 2432.58% in 2023.
  • Quarter analysis of 5 years shows Puma Biotechnology's Treasury Shares stood at $1.4 million in 2021, then rose by 7.32% to $1.5 million in 2022, then rose by 8.2% to $1.6 million in 2023, then decreased by 20.65% to $1.3 million in 2024, then rose by 5.38% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.8 million for Q2 2025, and $1.9 million during Q1 2025.